628nok
10,2 %
Date:2025-05-14Time:16:16:46Latest report:Q4-2024List:Oslo GrowthTicker:LYTIX
Market Cap:429 mnokEnterprise Value:301 mnokNet Sales:11,1 mnokEarnings:-94,3 mnokEmployees:0ISIN:NO0010405780

Ratios

10-year key figure history for Lytix Biopharma turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Lytix Biopharma with index and moving average MA50 and MA200.

Stockprice:6,28
MA50:5,18
MA200:6,64
Price/MA200:-5,4 %
RSI (14):73,2
Price/MA50:21,2 %

Description

Lytix Biopharma is a biotechnology company in the clinical stage that develops new cancer immunotherapies. The company's technology is based on research in antimicrobial peptides, a defense aimed at pathogens. Lytix Biopharma's main product, LTX-315, is an oncolytic peptide for the purpose of personalizing immunotherapy. The company conducts its research and operations in Oslo.

Biotechnology